Last updated: August 4, 2023

Summarytoggle arrow icon

Chickenpox (i.e., varicella) is an infection caused by the varicella zoster virus (VZV). The condition predominantly affects children. Transmission occurs via inhalation of airborne droplets and direct contact with respiratory secretions or skin lesion fluids. Chickenpox manifests with an intensely pruritic rash characterized by sequential clusters of papules, vesicles, and pustules in various stages of development; the rash may be preceded by a prodrome of constitutional symptoms. A clinical diagnosis is made based on the appearance of the rash; confirmatory testing may be obtained for atypical rashes or severe infection. In immunocompetent individuals, chickenpox is self-limiting and managed symptomatically. Antiviral therapy is reserved for patients with severe infection or at high risk for complications (e.g., bacterial superinfection, invasive infections). Following resolution, the virus remains latent in the sensory nerve root ganglia; it can reactivate (see “Shingles”) during episodes of stress or immunosuppression. Prevention includes routine vaccination and, when indicated, postexposure prophylaxis.

Epidemiologytoggle arrow icon

  • Primarily occurs in children
  • Before vaccines were widely introduced, ∼ 90% of all children had been infected by the age of 15.


Epidemiological data refers to the US, unless otherwise specified.

Etiologytoggle arrow icon

Risk factors for severe VZV infection [3][4][5]

Individuals with any of the following factors are at risk of severe primary infection if they have no evidence of VZV immunity:

Clinical featurestoggle arrow icon

  • Incubation period: ∼ 2 weeks [3]
  • Prodrome phase (rare in children) [7]
  • Exanthem phase: characterized by approx. 250–500 severely pruritic lesions in varying stages of development ; [3][7]
    • Lesion stages: papules→ superficial vesicles filled with clear fluid on an erythematous base (“dewdrop on rose petal” appearance) umbilicated and crusted pustules → scabs fall off after 1–3 weeks, (often leaving a depressed base)
    • Skin involvement [3][7][8]
      • Lesions first manifest centrally (i.e., face, scalp, and trunk) and spread to the extremities.
      • The rash is ultimately distributed across the body, with the highest concentration of lesions in the centeral areas.
      • The oral and urogenital mucous membranes are affected.
      • Ocular involvement may be present (see “VZV conjunctivitis”).
      • Palms and soles are typically spared.
    • Features of severe varicella infection may develop, e.g.: [3]
  • Latent phase: Following resolution of active skin infection, VZV remains latent in the sensory root ganglia; it can later reactivate (see "Shingles”). [7] [3]

Severe varicella infection is characterized by the prolonged eruption of vesicles, which are sometimes hemorrhagic, high fever > 1 week, and dissemination of VZV to the brain (encephalitis), liver (hepatitis), and/or lungs (pneumonia). [3]

Subtypes and variantstoggle arrow icon

Breakthrough varicella infection [3][9]

  • Definition: a wild-type VZV infection that occurs in individuals who have received ≥ 1 dose of the chickenpox vaccine ≥ 42 days prior to symptom onset [3][9][10]
  • Infectivity: infectious to close contacts [9]
  • Clinical features: generally mild compared to typical chickenpox infection [3]
    • Manifests ≥ 42 days following any dose of chickenpox immunization [9][10]
    • Shorter duration of illness and lower likelihood of fever
    • Typically < 50 skin lesions with few or no vesicles (predominantly maculopapular lesions)
  • Diagnosis: PCR test confirms a wild-type strain of VZV; see “Diagnostics of chickenpox.” [11][12]
  • Treatment: Usually supportive; follow varicella infection prevention measures to reduce spread.

Vaccine-associated chickenpox rash [3][9][13]

Diagnosticstoggle arrow icon

General principles

  • Typically diagnosed clinically based on characteristic clinical features
  • Confirmatory diagnostic studies are usually only considered in the following cases: [2][15]
    • Suspected VZV infection in patients with no rash or uncharacteristic rash
    • Vaccinated patients with suspected varicella
    • Patients with immunocompromised contacts
  • Additional studies may be required for patients with severe infections.

Confirmatory studies [15][16]

Chickenpox is usually diagnosed clinically. Obtain laboratory testing in case of atypical rash or severe infections. [2]

Additional studies

Consider in severe varicella zoster infection, depending on clinical features.

Visceral dissemination is more common in patients with HIV; consider HIV testing in patients with severe infection. [23]

Differential diagnosestoggle arrow icon

Chickenpox may be confused with other conditions that involve widespread vesicles and/or crusting lesions, e.g.: [3][7]

The differential diagnoses listed here are not exhaustive.

Treatmenttoggle arrow icon

Approach [2]

Most otherwise healthy children < 13 years of age with chickenpox can be treated with symptomatic treatment alone, but advise caregivers to return in the event of prolonged or worsening symptoms and/or signs of secondary bacterial skin infection. [2]

Supportive treatment [2]

  • Treat fever and pain with acetaminophen. [2]
  • Pruritus ; [28]
    • General advice for caregivers
      • Apply cool compresses.
      • Take lukewarm oatmeal baths.
      • Trim fingernails or wear mitts to prevent scratching.
    • Medications

Avoid use of aspirin and other salicylates (e.g., bismuth-subsalicylate) in children with chickenpox because of the risk of Reye syndrome. [3]

Avoid topical antihistamines and topical corticosteroids in patients with chickenpox because of the risk of systemic absorption when applied to large areas of skin. [29]

Antiviral therapy for VZV infection (high-risk patients only)

Patients with nonsevere infections and no risk factors for severe VZV infection do not require antiviral therapy and can be managed with supportive treatment only. [2]

Neonates, immunocompromised patients, and patients with severe infection should not receive oral acyclovir because of poor oral bioavailability. [3]

Complicationstoggle arrow icon

Adults have higher rates of complications from varicella compared to children. [2]

Skin [3]

Central nervous system [3][31]

Lungs [3]

Fetus (chickenpox during pregnancy) [3]

We list the most important complications. The selection is not exhaustive.

Prognosistoggle arrow icon

  • In healthy children, chickenpox infection generally has a benign course and heals without any consequences.
  • Residual scarring may occur because of excessive scratching or bacterial superinfection.
  • Immunosuppressed individuals are at a greater risk of the disease taking a generalized or even fatal course.


Preventiontoggle arrow icon


Most US states mandate reporting cases of chickenpox to local and/or state health departments. [32]

Evidence of VZV immunity [3][8][9]

Any of the following constitutes evidence of immunity to chickenpox: [9][33]

Varicella vaccine [34][35][36]

Recommend the varicella vaccine to all nonimmune children and adults who do not have contraindications to live vaccination. [37][39]

Postexposure prophylaxis for chickenpox [4][9]

General principles

Determining postexposure prophylaxis

Recommended management [3][9][41]
Evidence of VZV immunity No evidence of VZV immunity

Active immunization

Prophylaxis is not recommended for healthy individuals who are either too young for vaccination or who were exposed to VZV > 5 days prior to evaluation. [3]

Passive immunization

Controlling varicella transmission in healthcare settings [43]

Special patient groupstoggle arrow icon

Varicella in pregnancy [6][9]




Prevention of varicella in pregnancy [6][9]

Pregnant women should not receive the varicella vaccine. Nonimmune women should be vaccinated after delivery. [9]

Varicella in adults [1]



Varicella in patients with HIV [23]




  • Antiviral treatment is recommended. [23]
  • Discuss route of antiviral treatment with infectious diseases. [23]
    • Uncomplicated infection is usually treated with oral antivirals
    • Severe or complicated infection is usually treated with IV antivirals
  • See also “Treatment of chickenpox.”


Referencestoggle arrow icon

  1. Varicella. . Accessed: September 28, 2022.
  2. Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015; 1 (1).doi: 10.1038/nrdp.2015.16 . | Open in Read by QxMD
  3. AAP Committee on Infectious Diseases. Red Book: 2021–2024 Report of the Committee on Infectious Diseases. American Academy of Pediatrics ; 2021
  4. Lachiewicz AM, Srinivas ML. Varicella-zoster virus post-exposure management and prophylaxis: A review. Prev Med Rep. 2019; 16: p.101016.doi: 10.1016/j.pmedr.2019.101016 . | Open in Read by QxMD
  5. Blair RJ. Varicella Zoster Virus. Pediatr Rev. 2019; 40 (7): p.375-377.doi: 10.1542/pir.2017-0242 . | Open in Read by QxMD
  6. Committee on Practice Bulletins. Practice Bulletin No. 151: Cytomegalovirus, Parvovirus B19, Varicella Zoster, and Toxoplasmosis in Pregnancy. Obstetrics & Gynecology. 2015; 125 (6): p.1510-1525.doi: 10.1097/01.aog.0000466430.19823.53 . | Open in Read by QxMD
  7. Wolff K, Johnson RA, Suurmond D. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology. McGraw-Hill Medical ; 2005
  8. Blaney SM, Giardino AP, Orange JS, et al. Rudolph's Pediatrics, 23rd Edition. McGraw-Hill Education / Medical ; 2018
  9. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56 (RR-4): p.1-40.
  10. Leung J, Broder KR, Marin M. Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): a systematic literature review. Expert Rev Vaccines. 2017; 16 (4): p.391-400.doi: 10.1080/14760584.2017.1294069 . | Open in Read by QxMD
  11. Quinlivan ML, Gershon AA, Steinberg SP, Breuer J. Rashes Occurring after Immunization with a Mixture of Viruses in the Oka Vaccine Are Derived from Single Clones of Virus. J Infect Dis. 2004; 190 (4): p.793-796.doi: 10.1086/423210 . | Open in Read by QxMD
  12. Galea SA, Sweet A, Beninger P, et al. The Safety Profile of Varicella Vaccine: A 10‐Year Review. J Infect Dis. 2008; 197 (s2): p.S165-S169.doi: 10.1086/522125 . | Open in Read by QxMD
  13. Varicella Vaccine Safety and Monitoring Information for Healthcare Providers. Updated: April 5, 2012. Accessed: August 5, 2022.
  14. Bernstein P, Furuya Y, Steinberg S, Scully B, Larussa P, Gershon AA. Vaccine-related varicella-zoster rash in a hospitalized immunocompetent patient. Am J Infect Control. 2011; 39 (3): p.247-9.doi: 10.1016/j.ajic.2010.06.027 . | Open in Read by QxMD
  15. Chickenpox (Varicella) interpreting laboratory tests. Updated: April 28, 2021. Accessed: August 5, 2022.
  16. Collecting Specimens for Varicella Zoster Virus (VZV) Testing. Updated: April 28, 2021. Accessed: August 5, 2022.
  17. Sauerbrei A. Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections. European Journal of Clinical Microbiology & Infectious Diseases. 2016; 35 (5): p.723-734.doi: 10.1007/s10096-016-2605-0 . | Open in Read by QxMD
  18. Mandelbrot L. Fetal varicella - diagnosis, management, and outcome. Prenat Diagn. 2012; 32 (6): p.511-518.doi: 10.1002/pd.3843 . | Open in Read by QxMD
  19. Kelly B, Shimoni T. Reintroducing the Tzanck Smear. Am J Clin Dermatol. 2009; 10 (3): p.141-152.doi: 10.2165/00128071-200910030-00001 . | Open in Read by QxMD
  20. Mylarapu A, Yarabarla V, Padilla RM, Fasen M, Reddy P. Healed Varicella Pneumonia: A Case of Diffuse Pulmonary Microcalcifications. Cureus. 2021; 13 (6): p.e15890.doi: 10.7759/cureus.15890 . | Open in Read by QxMD
  21. Alvarez JC, Alvarez J, Tinoco J, et al. Varicella-Zoster Virus Meningitis and Encephalitis: An Understated Cause of Central Nervous System Infections. Cureus. 2020; 12 (11): p.e11583.doi: 10.7759/cureus.11583 . | Open in Read by QxMD
  22. Haaga JR, Boll D. Computed Tomography & Magnetic Resonance Imaging Of The Whole Body E-Book. Elsevier Health Sciences ; 2016
  23. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: 2021 update. Updated: June 22, 2021. Accessed: August 18, 2021.
  24. Buttery VW, Kenyon C, Grunewald S, et al. Atypical Presentations of Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6 — Minnesota, 2014. MMWR Morb Mortal Wkly Rep. 2015; 64 (30): p.805.doi: 10.15585/mmwr.mm6429a8 . | Open in Read by QxMD
  25. Centers for Disease Control and Prevention (CDC). Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6 - Alabama, Connecticut, California, and Nevada, November 2011-February 2012. MMWR Morb Mortal Wkly Rep. 2012; 61 (12): p.213-4.
  26. Reed JL, Scott DE, Bray M. Eczema Vaccinatum. Clin Infect Dis. 2012; 54 (6): p.832-840.doi: 10.1093/cid/cir952 . | Open in Read by QxMD
  27. Monkeypox and Smallpox Vaccine Guidance. Updated: December 2, 2019. Accessed: May 23, 2022.
  28. Usatine R. Color Atlas of Family Medicine 2/E. McGraw Hill Professional ; 2013
  29. Mohundro BL, Horace A. Itching like crazy: understanding chickenpox. US Pharm. 2012; 37 (3): p.58-60.
  30. Gilbert, DN; Chambers, HF. Sanford Guide to Antimicrobial Therapy 2020. Antimicrobial Therapy, Inc ; 2020
  31. Barkovich AJ. Pediatric Neuroimaging. Lippincott Williams & Wilkins ; 2005
  32. Varicella Reporting and Surveillance. Updated: April 28, 2021. Accessed: August 8, 2022.
  33. Immunity Against (Protection From) Chickenpox. Updated: April 5, 2012. Accessed: August 9, 2022.
  34. Child and Adolescent Immunization Schedule. Recommendations for Ages 18 Years or Younger, United States, 2023. Updated: February 10, 2023. Accessed: March 24, 2023.
  35. Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind Recommendations for Ages 18 Years or Younger, United States, 2023. Updated: February 10, 2023. Accessed: March 24, 2023.
  36. Adult Immunization Schedule by Age Recommendations for Ages 19 Years or Older, United States, 2023. Updated: February 10, 2023. Accessed: March 24, 2023.
  37. Child and Adolescent Immunization Schedule. Recommendations for Ages 18 Years or Younger, United States, 2022. Updated: February 17, 2022. Accessed: August 9, 2022.
  38. Klein NP, Fireman B, Yih WK, et al. Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures. Pediatrics. 2010; 126 (1): p.e1-e8.doi: 10.1542/peds.2010-0665 . | Open in Read by QxMD
  39. Murthy N, Wodi AP, Bernstein H, Ault KA. Recommended Adult Immunization Schedule, United States, 2022. Ann Intern Med. 2022.doi: 10.7326/m22-0036 . | Open in Read by QxMD
  40. Sampathkumar P, Drage LA, Martin DP. Herpes Zoster (Shingles) and Postherpetic Neuralgia. Mayo Clinic Proceedings. 2009; 84 (3): p.274-280.doi: 10.4065/84.3.274 . | Open in Read by QxMD
  41. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep. 2013; 62 (28): p.574-6.
  42. Timing and Spacing of Immunobiologics, General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Updated: July 12, 2022. Accessed: August 9, 2022.
  43. Advisory Committee on Immunization Practices., Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60 (RR-7): p.1-45.

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer